Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome
Although statistical significance was narrowly missed, soticlestat showed a numerical benefit over placebo for convulsive seizure decrease. Clinically meaningful benefits across multiple secondary endpoints were observed. No new safety concerns emerged.
Authors
- Mahnaz Asgharnejad (ORCID: https://orcid.org/0000-0001-8060-2148)
- Kette D. R. Valente (ORCID: https://orcid.org/0000-0002-5008-0809)
- Eiji Nakagawa
- Cheng Dong
- Philipp von Rosenstiel (ORCID: https://orcid.org/0000-0003-1709-1271)
- R. Nabbout
- J. P. Sullivan (ORCID: https://orcid.org/0000-0002-9067-1531)
- Venkatesha Murthy
- Sarah Sheikh
- Adam Strzelczyk
- S. Hsiao
- Yuehua Zhang
- Marta Zolnowska
- Vicente Villanueva
- Yasir Khan
Institutions
- Goethe University Frankfurt (DE)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- University of California, San Francisco (US)
- Peking University (CN)
- University School of Physical Education in Kraków (PL)
- Hospital Universitari i Politècnic La Fe (ES)
- National Center of Neurology and Psychiatry (JP)
- Peking University First Hospital (CN)
- Takeda (United States) (US)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Fundação Faculdade de Medicina (BR)
Publication Details
- Journal
- Epilepsia
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1002/epi.70164
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00